Every year, over 50,000 women in the United States are diagnosed with the non-lethal form of breast cancer known as ductal carcinoma in situ (DCIS). When a diagnosis of DCIS is confirmed on biopsy, most women are treated with partial mastectomy and breast irradiation or elect total mastectomy as a means to avoid radiation therapy. Newer approaches to treatment for DCIS have suggested that surgical excision and observation, with or without endocrine therapy, may be an alternative for small volume, low grade DCIS. However, as a general rule, the underlying biology of DCIS is just beginning to be considered in the context of treating DCIS. A substantial body of basic science regarding the underlying molecular alterations present in DCIS suggests there are two major pathways of progression constituting an indolent and aggressive form of DCIS. The goal of this proposal Is to translate the research data on the numerous molecular genetic abnormalities present In DCIS into a pathology classification algorithm based on a restricted set of molecular, immunohistochemical, or morphologic features that will reliably Identify low grade and high grade progression pathways in DCIS. This would promote conservative treatment strategies for a subset of women with favorable prognosis DCIS and reduce the potential unfavorable consequences of over treating indolent breast disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA163303-02
Application #
8555417
Study Section
Special Emphasis Panel (ZCA1-SRLB-R (O1))
Project Start
2011-09-23
Project End
2016-05-31
Budget Start
2012-09-01
Budget End
2013-05-31
Support Year
2
Fiscal Year
2012
Total Cost
$191,175
Indirect Cost
$66,739
Name
University of Vermont & St Agric College
Department
Type
DUNS #
066811191
City
Burlington
State
VT
Country
United States
Zip Code
05405
Onega, Tracy; Weaver, Donald L; Frederick, Paul D et al. (2017) The diagnostic challenge of low-grade ductal carcinoma in situ. Eur J Cancer 80:39-47
Engmann, Natalie J; Golmakani, Marzieh K; Miglioretti, Diana L et al. (2017) Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer. JAMA Oncol 3:1228-1236
Samples, Laura S; Rendi, Mara H; Frederick, Paul D et al. (2017) Surgical implications and variability in the use of the flat epithelial atypia diagnosis on breast biopsy specimens. Breast 34:34-43
Onega, Tracy; Weiss, Julie E; Goodrich, Martha E et al. (2017) Relationship between preoperative breast MRI and surgical treatment of non-metastatic breast cancer. J Surg Oncol 116:1008-1015
Knerr, Sarah; Wernli, Karen J; Leppig, Kathleen et al. (2017) A web-based personalized risk communication and decision-making tool for women with dense breasts: Design and methods of a randomized controlled trial within an integrated health care system. Contemp Clin Trials 56:25-33
Haas, Jennifer S; Barlow, William E; Schapira, Marilyn M et al. (2017) Primary Care Providers' Beliefs and Recommendations and Use of Screening Mammography by their Patients. J Gen Intern Med 32:449-457
Jackson, Sara L; Frederick, Paul D; Pepe, Margaret S et al. (2017) Diagnostic Reproducibility: What Happens When the Same Pathologist Interprets the Same Breast Biopsy Specimen at Two Points in Time? Ann Surg Oncol 24:1234-1241
Shiyanbola, Oyewale O; Arao, Robert F; Miglioretti, Diana L et al. (2017) Emerging Trends in Family History of Breast Cancer and Associated Risk. Cancer Epidemiol Biomarkers Prev 26:1753-1760
Lehman, Constance D; Arao, Robert F; Sprague, Brian L et al. (2017) National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer Surveillance Consortium. Radiology 283:49-58
Leopold, Robin B; Thomas, Alexander W; Concannon, Kyle F et al. (2017) Breast cancer screening in patients with cancers other than breast. Breast Cancer Res Treat 163:343-348

Showing the most recent 10 out of 74 publications